GlassScriptPhysician profile
Rani Chithra John
NPI 1225786247
$2,164.12
in general payments reported to CMS, 2019-2025
15 companies · $557 in 2025
The $557 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $244 · 2023: $576 · 2024: $787 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,920.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,920.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $325.82 | 2024-2025 | Repatha, Evenity |
| Lilly USA, LLC | $283.16 | 2023-2025 | Jardiance, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.06 | 2022-2024 | Jardiance |
| Abbvie INC. | $224.99 | 2023 | |
| Novo Nordisk INC | $208.82 | 2023-2024 | Wegovy |
| Madrigal Pharmaceuticals | $122.84 | 2025 | Rezdiffra |
| Biohaven Pharmaceutical Holding Company LTD. | $121.09 | 2022 | |
| Esperion Therapeutics, INC. | $115.53 | 2024 | Nexletol, Nexlizet |
| Idorsia Pharmaceuticals US INC | $114.43 | 2023 | Quviviq |
| Ascensia Diabetes Care US INC. | $110.74 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $109.13 | 2024 | Zeposia |
| Alnylam Pharmaceuticals INC. | $81.46 | 2023 | Amvuttra |
| Pfizer INC. | $66.68 | 2025 | |
| Exact Sciences Corporation | $17.24 | 2025 | The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $15.13 | 2023 | Nuedexta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rani John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.